Paraoxonase, arylesterase and lactonase activities of paraoxonase-1 (PON1) in obese and severely obese women
- 23 November 2017
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 78 (1-2) , 18-24
Abstract
Obesity is independently associated with disturbances in lipid and lipoprotein metabolism, oxidative stress, and is a well-established independent risk factor for cardiovascular diseases (CVD). Human paraoxonase 1 (PON1) is a pleotropic high-density lipoprotein (HDL)-associated enzyme with antioxidant and anti-inflammatory proprieties that have been suggested to contribute to the athero-protective function of the lipoprotein. The aim of this study was to investigate whether obesity is associated with PON1 activity and whether this association is influenced by oxidative stress, inflammation and HDL cholesterol (HDL-C) concentration. The promiscuous activities, arylesterase and paraoxonase, and the putative physiological activity, lactonase, of PON1 were assessed in the serum of 214 obese and severely obese, 101 overweight and 129 normal-weight women. Levels of high-sensitivity C-reactive protein (hs-CRP), hydroperoxides (by-products of lipid oxidative damage) and lipid profiles were also evaluated. Arylesterase activity was the only activity that significantly differed across the groups (ANOVA, p < .01), with the greatest decrease observed in individuals with body mass index (BMI) > 40 kg/m2 compared to controls (p < .001). This activity was also inversely, although weakly (r = −0.160, p < .001) correlated with the BMI, and the association was independent of age and levels of oxidative stress and inflammation, but not of HDL-C concentration. In conclusion, our results suggest that the apparent obesity-associated decrement of PON1 activity might simply reflect the decrease in concentration of its plasmatic carrier.Keywords
Funding Information
- University of Ferrara
This publication has 51 references indexed in Scilit:
- Oxidative Challenge in Alzheimer's Disease: State of Knowledge and Future NeedsJournal of Investigative Medicine, 2016
- Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological rolesGene, 2015
- Clinical and Genetic Association of Serum Paraoxonase and Arylesterase Activities With Cardiovascular RiskArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery diseaseJournal of Clinical Investigation, 2011
- The paraoxonases: role in human diseases and methodological difficulties in measurementCritical Reviews in Clinical Laboratory Sciences, 2009
- The Catalytic Histidine Dyad of High Density Lipoprotein-associated Serum Paraoxonase-1 (PON1) Is Essential for PON1-mediated Inhibition of Low Density Lipoprotein Oxidation and Stimulation of Macrophage Cholesterol EffluxJournal of Biological Chemistry, 2006
- Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificitiesJournal of Lipid Research, 2005
- Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymesNature Structural & Molecular Biology, 2004
- Decreased Atherosclerotic Lesion Formation in Human Serum Paraoxonase Transgenic MiceCirculation, 2002
- Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidantsFree Radical Biology and Medicine, 1999